| Administration with telomeric DNA telomere-like oligonucleotides induces enhancement of telomerase activity and resistance against oxidative stress in telomere reverse transcriptase gene-transfected human fibroblasts. | |
| | |
MedLine Citation:
|
PMID: 20347571 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Out of normal human fibroblasts OUMS-36 and three clones (T1, T2 and T3) of telomere reverse transcriptase gene (hTERT)-transfectants, telomere length is in order: T3 >T2 >T1 >>OUMS-36 (young) >>OUMS-36 (old), and telomerase activity is in order: T2 >T3 >T1 >>OUMS-36 (young, old), suggesting that telomere length may be roughly governed by telomerase activity. Telomere-like oligonucleotides [5'- (TTAGGG) (1-3)-3'] (ON mono-/di-/trimer) and a mononucleotide (T:A:G=2:1:3, mol/mol) mixture (MN mix), as candidates for telomerase activators, maintained above 80% of cell viability at marginally higher doses of 2 μM for MN-mix or ON monomer, 1 μM for ON dimmer and 0.67 μM for ON trimer, respectively, in OUMS-36 and T2 cells, and administered for 4 weeks, resulting in no elongation of telomere length in both the cell lines. In contrast, telomerase activity was enhanced by administration with ON mono-/di-/trimer, but not MN mix, in a manner dependent on treatment periods, in T2 transfectants, whereas similar effects were not observed in OUMS-36 parents. The 4-week treatment with ON mono-/di-/trimers, but not MN mix, also suppressed cell-viability diminishment induced by the oxidative-stressor tert-butylhydroperoxide in T2 cells, but scarcely in OUMS-36 cells. Thus, the promoting effects of oligonucleotide [5'-(TTAGGG)(1-3)-3'] on both telomerase enhancement and oxidative-stress resistance can be exerted for telomerase-abundant T2 hTERT-transfectants, but not for telomerase-poor OUMS-36 parents. |
| | |
Authors:
|
Shin Watanabe; Yasukazu Saitoh; Masayoshi Namba; Nobuhiko Miwa |
Publication Detail:
|
Type: Journal Article Date: 2010-03-11 |
Journal Detail:
|
Title: Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie Volume: 64 ISSN: 1950-6007 ISO Abbreviation: Biomed. Pharmacother. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8213295 Medline TA: Biomed Pharmacother Country: France |
Other Details:
|
Languages: eng Pagination: 565-71 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Masson SAS. All rights reserved. |
Affiliation:
|
Laboratory of Cell Death Control BioTechnology, Hiroshima Prefectural University School of BioSciences, Shobara, Hiroshima 727-0023, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gene expression analysis on the liver of cholestyramine-treated type 2 diabetic model mice.
Next Document: Ex vivo assays of CEM cells cultured and treated in the three dimensional cultures.